High ME1 Expression Is a Molecular Predictor of Post-Transplant Survival of Patients with Acute Myeloid Leukemia

César Alexander Ortiz Rojas, Abel Costa-Neto, Diego A. Pereira-Martins, Duy Minh Le, Dominique Sternadt, Isabel Weinhäuser, Gerwin Huls, Jan Jacob Schuringa, Eduardo Magalhães Rego*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

18 Downloads (Pure)


Several laboratory and clinical variables have been reported to be associated with the outcome of intensive chemotherapy for acute myeloid leukemia (AML), but only a few have been tested in the context of hematopoietic stem cell transplant (HSCT). This study aimed to identify genes whose expression of AML at diagnosis were associated with survival after HSCT. For this purpose, three publicly available adult AML cohorts (TCGA, BeatAML, and HOVON), whose patients were treated with intensive chemotherapy and then subjected to allogeneic or autologous HSCT, were included in this study. After whole transcriptome analysis, we identified ME1 as the only gene whose high expression was associated with shorter survival in patients subjected to HSCT. In addition, the inclusion of ME1 expression was able to improve the European LeukemiaNet risk stratification. Pathways related to lipid biosynthesis, mainly fatty acids, and cholesterol were positively correlated with ME1 expression. Furthermore, ME1 expression was associated with an M2 macrophage-enriched microenvironment, mature AML blasts hierarchy, and oxidative phosphorylation metabolism. Therefore, ME1 expression can be used as biomarker of poor response to HSCT in AML.

Original languageEnglish
Article number296
Number of pages17
Issue number1
Publication statusPublished - Jan-2023


  • acute myeloid leukemia
  • biomarker
  • hematopoietic stem cell transplantation
  • ME1
  • prognosis

Cite this